Alkermes plc
ALKS
Updated: 24/09/2026, 07:36:08
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
No summaries found.
- Share price
- $42.13
- Market cap
- $7.07B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Blair Jackson
- Employees
- 2,050
- IPO date
- 16/07/1991
- Beta
- 0.26
- Last dividend
- $0.00
- Day range
- $41.23 – $43.58
- 52-week range
- $26.99 – $55.67
- 1-day performance
- -2.68%
- 1-year performance
- 56.09%
- Current drawdown (1Y)
- -24.32%
- CIK
- 0001520262
- CUSIP
- G01767105
- ISIN
- IE00B56GVS15
- Created
- 07/12/2025, 02:02:09
- Last update
- 24/09/2026, 07:36:08
Track Alkermes plc with an AI analyst
See which prediction-market events move ALKS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
MarketBeat • STOCK • 10/06/2026, 16:09:34
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
GuruFocus • STOCK • 09/06/2026, 21:57:00
Alkermes (ALKS) Hits New Highs Amid Q1 Growth & Insider Sales
Market Data • Market Data • 04/06/2026, 23:07:47
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Benzinga • STOCK • 12/05/2026, 16:27:41
Alkermes (NASDAQ: ALKS) Price Target Raised Amid Strong Financial Performance and Strategic Shift
Market Data • Market Data • 06/05/2026, 17:14:23
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
Zacks Investment Research • STOCK • 06/05/2026, 15:10:18
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
Seeking Alpha • STOCK • 06/05/2026, 09:30:08
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 17:41:25
Alkermes (NASDAQ: ALKS) Insider Sells Shares Ahead of Q1 Earnings Report
Market Data • Market Data • 02/05/2026, 04:05:37
Alkermes plc (NASDAQ:ALKS) Stock Analysis: Insider Transactions, Momentum, and Financial Health
Market Data • Market Data • 02/04/2026, 02:00:17
Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?
Zacks Investment Research • STOCK • 27/03/2026, 13:32:09
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS
Defense World • STOCK • 14/03/2026, 04:07:17